Puma Biotechnology - PBYI Stock Forecast, Price & News

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology Stock Up 4.6 %

Shares of PBYI Stock traded up $0.16 during mid-day trading on Tuesday, hitting $3.65. The company's stock had a trading volume of 304,558 shares, compared to its average volume of 476,090. Puma Biotechnology has a 52-week low of $1.60 and a 52-week high of $7.84. The business has a 50-day moving average price of $2.90 and a 200 day moving average price of $2.63. The company has a debt-to-equity ratio of 13.63, a quick ratio of 1.47 and a current ratio of 1.57. The stock has a market cap of $166.28 million, a price-to-earnings ratio of -4.24 and a beta of 0.66.

Analyst Upgrades and Downgrades

Several research analysts have commented on PBYI shares. StockNews.com upgraded Puma Biotechnology from a "hold" rating to a "buy" rating in a research note on Monday. HC Wainwright decreased their price objective on Puma Biotechnology from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday.

Insider Buying and Selling at Puma Biotechnology

In related news, Director Troy Edward Wilson sold 27,858 shares of the stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $2.58, for a total transaction of $71,873.64. Following the completion of the transaction, the director now directly owns 27,350 shares of the company's stock, valued at $70,563. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Troy Edward Wilson sold 27,858 shares of the stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $2.58, for a total value of $71,873.64. Following the sale, the director now directly owns 27,350 shares in the company, valued at $70,563. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Alan H. Auerbach sold 26,140 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $2.63, for a total value of $68,748.20. Following the completion of the sale, the chief executive officer now owns 6,317,952 shares in the company, valued at $16,616,213.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,372 shares of company stock valued at $174,913. Company insiders own 21.20% of the company's stock.